Riedinger CJ, Barrington DA, Nagel CI, Khadraoui WK, Haight PJ, Tubbs C, Backes FJ, Cohn DE, O'Malley DM, Copeland LJ, Chambers LM
Gynecol Oncol 183 R1Retraction notice to "Cost-effectiveness of chemotherapy and dostarlimab for
Retraction notice to "Cost-effectiveness of chemotherapy and dostarlimab for
advanced or recurrent endometrial cancer" [Gynecologic Oncology 183 (2024) 78-84].
April 1, 2024 at 12:00 AM